Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Lorna HopcroftEleanor M WigmoreStuart Charles WilliamsonSusana RosCath EberleinJennifer I MossJelena UrosevicLarissa S CarnevalliSara TalbotLauren BradshawCatherine BlakerSreeharsha GundaVenetia OwensonScott HoffmannDaniel SuttonStewart JonesRichard J A GoodwinBrandon S WillisClaire RooneyElza C de BruinSimon T BarryPublished in: NPJ breast cancer (2023)